Beckman Coulter/Princeton BioMeditech agreement
In a move that underscores its growing commitment to the market for rapid diagnostic medical test products, Beckman Coulter has entered into a supply relationship with Princeton BioMeditech (PBM). Under the agreement, PBM will supply a wide range of rapid diagnostic tools used at the point of medical care to Beckman Coulter's Primary Care Diagnostics business unit (PCD).
Princeton BioMeditech is a leading innovator and manufacturer of simple and rapid diagnostic products used at the point of care. The company offers more than 70 tests covering fertility management, infectious diseases, cardiac markers, drugs of abuse, cancer markers, environmental and veterinary diagnostics that enable consumers and professionals to improve speed and quality of diagnosis for better patient care.
Scientist salaries increase but pay gap persists: report
Average salaries for members of Australia's STEM sectors have grown in the past year, but...
100 ARC Future Fellows to share $87.8 million
The Australian Government is investing in Australia's smartest minds to conduct research that...
Award-winning study finds antioxidants improve embryo development
The presence of antioxidants during IVF and embryo culture significantly increased embryo quality...
